China Meheco Group Co Ltd
SSE:600056
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China Meheco Group Co Ltd
Interest Income Expense
China Meheco Group Co Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Meheco Group Co Ltd
SSE:600056
|
Interest Income Expense
-¥26m
|
CAGR 3-Years
45%
|
CAGR 5-Years
34%
|
CAGR 10-Years
8%
|
|
|
COSCO SHIPPING Development Co Ltd
SSE:601866
|
Interest Income Expense
-¥1.6B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-66%
|
CAGR 10-Years
N/A
|
|
|
Sichuan New Energy Power Co Ltd
SZSE:000155
|
Interest Income Expense
-¥204.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
|
C
|
CITIC Metal Co Ltd
SSE:601061
|
Interest Income Expense
¥1.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
China National Uranium Co Ltd
SZSE:001280
|
Interest Income Expense
¥124.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
JINGDONG Industrials Inc
HKEX:7618
|
Interest Income Expense
¥61.5m
|
CAGR 3-Years
108%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
China Meheco Group Co Ltd
Glance View
China Meheco Group Co., Ltd., established in 1984, stands as a prominent player in the Chinese pharmaceutical and healthcare sector. As the company evolved over the decades, it navigated the complex Chinese market by strategically positioning itself across the entire pharmaceutical value chain. This involved investing heavily in research and development, securing partnerships with both domestic and international pharmaceutical companies, and streamlining its distribution network to enhance efficiency. Such endeavors have enabled China Meheco to develop and distribute a wide range of medical products, including active pharmaceutical ingredients, finished drugs, medical devices, and traditional Chinese medicines. The company leverages its robust R&D capabilities to continually bring innovative products to market, which has been a significant source of its revenue. China Meheco's business model thrives on its expansive distribution network and strategic collaborations. By aligning with global pharmaceutical giants, the company not only gains access to cutting-edge technologies and advanced formulations but also expands its market reach beyond China. This dual strategy of innovation and partnership ensures a steady flow of products that cater to diverse healthcare needs. Furthermore, China Meheco capitalizes on its local expertise and deep understanding of regulatory frameworks, allowing it to maneuver efficiently within China's complex healthcare landscape. This approach underpins its ability to capture substantial market share in a competitive industry, driving profitability and positioning the company as a key player in the global pharmaceutical arena.
See Also
What is China Meheco Group Co Ltd's Interest Income Expense?
Interest Income Expense
-26m
CNY
Based on the financial report for Sep 30, 2025, China Meheco Group Co Ltd's Interest Income Expense amounts to -26m CNY.
What is China Meheco Group Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
8%
Over the last year, the Interest Income Expense growth was 88%. The average annual Interest Income Expense growth rates for China Meheco Group Co Ltd have been 45% over the past three years , 34% over the past five years , and 8% over the past ten years .